CN110128445B - P-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, and preparation method and application thereof - Google Patents
P-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, and preparation method and application thereof Download PDFInfo
- Publication number
- CN110128445B CN110128445B CN201910530410.XA CN201910530410A CN110128445B CN 110128445 B CN110128445 B CN 110128445B CN 201910530410 A CN201910530410 A CN 201910530410A CN 110128445 B CN110128445 B CN 110128445B
- Authority
- CN
- China
- Prior art keywords
- indazole
- isoxazole
- dihydro
- phenyl
- benzopyran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of medicines, and particularly relates to p-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole]Derivatives, and a preparation method and application thereof. The invention relates to a p-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole]The preparation method of the derivative comprises the following steps: (1) synthesizing 6-bromo-4-oxo-4H-benzopyran-3-formaldehyde oxime; (2)5- (4-chlorobenzylidene) -1-phenyl-6, 7-dihydro-1H-synthesis of indazol-4 (5H) -one; (3) 5- (4-chlorobenzylidene) -1-phenyl-6, 7-dihydro-1HThe (E) -indazole-4 (5H) -ketone and a compound 6-bromo-4-oxo-4H-benzopyran-3-formaldehyde oxime undergo 1, 3-dipolar cycloaddition reaction under the action of chloramine T to obtain spiro [ indazole-isoxazole with p-chlorophenyl substituted chromone structure]And (3) derivatives.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a p-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, and a preparation method and application thereof.
Background
5- (4-chlorobenzylidene) -1-phenyl-6, 7-dihydro-1H-indazol-4 (5H) -one, having the following chemical structure:
the 1, 3-dipolar cycloaddition reaction is the most important method for synthesizing five-membered heterocyclic compounds with good regioselectivity and body selectivity, and is also a more active reaction in heterocyclic pharmaceutical chemistry research. In recent years, chromones have received much attention due to a wide range of biological activities, such as anticancer, antibacterial, inhibition of platelet aggregation, and the like. The isoxazole skeleton is an important pharmacophore in the application of medicines, and has remarkable physiological and pharmacological activities. In addition, spiroisoxazoles synthesized by 1, 3-dipolar cycloaddition of nitrile oxides to exocyclic double bonds have attracted attention by pharmacologists because they exhibit some important physiological properties. Therefore, the heterocyclic compound has high synthetic value in terms of pharmacology and synthesis angle.
In order to better study the influence of different heterocycles on the pharmacological activity caused by the aggregation in the same molecule, a p-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative is synthesized through a 1, 3-dipolar cycloaddition reaction.
Disclosure of Invention
The invention aims to provide a p-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, and a preparation method and application thereof.
In order to achieve the purpose, the technical scheme of the invention is as follows:
the chemical structural formula of a p-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative is as follows:
wherein: Ar-4-ClC6H4-。
A preparation method of p-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivatives comprises the following steps:
(1) synthesis of 6-bromo-4-oxo-4H-benzopyran-3-carbaldehyde oxime: adding 50.0mL of 6-bromo-4-oxo-4H-benzopyran-3-formaldehyde into ethanol, completely dissolving 316.0mg of hydroxylamine hydrochloride and 464.0mg of sodium acetate in distilled water, dropwise adding the solution into the former solution by using a constant-pressure dropping funnel, heating, refluxing, tracking by TLC (thin layer chromatography), cooling to room temperature after the reaction is finished, carrying out suction filtration, washing with water, and recrystallizing a product by using 95% ethanol to obtain 6-bromo-4-oxo-4H-benzopyran-3-formaldehyde oxime;
(2) synthesis of 5- (4-chlorobenzylidene) -1-phenyl-6, 7-dihydro-1H-indazol-4 (5H) -one: dissolving 10mmol of 1-phenyl-6, 7-dihydro-1H-indazole-4 (5H) -ketone and 10mmol of p-chlorobenzaldehyde in 10mL of ethanol, adding 2mL of 40% NaOH aqueous solution, stirring at 80 ℃ for 3 hours, filtering and separating by using a Buchner funnel, washing a filter cake with water, recrystallizing and purifying by using ethanol, filtering and drying to obtain a product, namely 5- (4-chlorobenzylidene) -1-phenyl-6, 7-dihydro-1H-indazole-4 (5H) -ketone;
(3) adding 5- (4-chlorobenzylidene) -1-phenyl-6, 7-dihydro-1H-indazole-4 (5H) -one and 6-bromo-4-oxo-4H-benzopyran-3-formaldehyde oxime into 30mL of absolute ethyl alcohol for dissolving, adding chloramine T inorganic salt, refluxing for 12 hours, carrying out 1, 3-dipolar cycloaddition reaction, tracking by TLC, removing the solvent by reduced pressure rotary distillation after the reaction is completed, dissolving 3mL of ethyl acetate for standby, and finally carrying out chromatographic separation by using a developing agent silica gel column to obtain the spiro [ indazole-isoxazole ] derivative with the p-chlorophenyl substituted chromone structure.
In the step (3), the ratio of the chloramine T inorganic salt to the 6-bromo-4-oxo-4H-benzopyran-3-formaldehyde oxime to the 5- (4-chlorobenzylidene) -1-phenyl-6, 7-dihydro-1H-indazol-4 (5H) -one substance is 7:6: 5.
The developing solvent in the step (3) is ethyl acetate and petroleum ether, and the volume ratio of the ethyl acetate to the petroleum ether is V(Ethyl acetate):V(Petroleum ether)＝1:5。
An application of p-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivatives in antitumor drugs.
The invention provides a p-chlorophenyl substituted spiro [ indazole-isoxazole ] derivative containing a chromone structure and a preparation method thereof, wherein the preparation method comprises the step of introducing an isoxazole ring and a chromone structure into a 5- (4-chlorobenzylidene) -1-phenyl-6, 7-dihydro-1H-indazole-4 (5H) -one structure by using a 1, 3-dipolar cycloaddition method, so that the spiro [ indazole-isoxazole ] derivative containing the chromone structure is synthesized. The prepared spiro [ indazole-isoxazole ] derivative containing the chromone structure has stronger tumor cell inhibition and anti-inflammatory effects, and provides a basis for further application in the field of medicines.
Drawings
FIG. 1 is a scheme showing the preparation of 6-bromo-4-oxo-4H-benzopyran-3-carbaldehyde oxime (Compound 2) in accordance with the present invention;
FIG. 2 is a scheme showing the preparation of 5- (4-chlorobenzylidene) -1-phenyl-6, 7-dihydro-1H-indazol-4 (5H) -one (Compound 3) according to the present invention;
fig. 3 is a preparation scheme of a p-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative (compound 4) in the present invention.
Detailed Description
The technical solutions of the present invention are further described in detail below with reference to the drawings and examples, which should not be construed as limiting the present invention.
Chromones are receiving much attention due to a wide range of biological activities, such as anticancer, antibacterial, inhibition of platelet aggregation, and the like. In order to better study the influence of different heterocycles on the pharmacological activity caused by the aggregation in the same molecule, a p-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative is synthesized through a 1, 3-dipolar cycloaddition reaction.
The invention provides a p-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, which has the following chemical structural formula:
wherein: Ar-4-ClC6H4-。
This example is a method for preparing p-chlorophenyl substituted spiro [ indazole-isoxazole ] derivatives containing chromone structures, comprising:
(1) synthesis of 6-bromo-4-oxo-4H-benzopyran-3-carbaldehyde oxime: adding 50.0mL of 6-bromo-4-oxo-4H-benzopyran-3-formaldehyde into ethanol, completely dissolving 316.0mg of hydroxylamine hydrochloride and 464.0mg of sodium acetate in distilled water, dropwise adding the solution into the former solution by using a constant-pressure dropping funnel, heating, refluxing, tracking by TLC (thin layer chromatography), cooling to room temperature after the reaction is finished, carrying out suction filtration, washing with water, and recrystallizing a product by using 95% ethanol to obtain 6-bromo-4-oxo-4H-benzopyran-3-formaldehyde oxime;
(2) synthesis of 5- (4-chlorobenzylidene) -1-phenyl-6, 7-dihydro-1H-indazol-4 (5H) -one: dissolving 10mmol of 1-phenyl-6, 7-dihydro-1H-indazole-4 (5H) -ketone and 10mmol of p-chlorobenzaldehyde in 10mL of ethanol, adding 2mL of 40% NaOH aqueous solution, stirring at 80 ℃ for 3 hours, filtering and separating by using a Buchner funnel, washing a filter cake with water, recrystallizing and purifying by using ethanol, filtering and drying to obtain a product, namely 5- (4-chlorobenzylidene) -1-phenyl-6, 7-dihydro-1H-indazole-4 (5H) -ketone;
(3) adding 1mmol of 5- (4-chlorobenzylidene) -1-phenyl-6, 7-dihydro-1H-indazole-4 (5H) -one and 1.2mmol of 6-bromo-4-oxo-4H-benzopyran-3-formaldehyde oxime into 30mL of absolute ethyl alcohol, dissolving, adding 1.4mmol of chloramine T inorganic salt, refluxing for 12 hours, carrying out 1, 3-dipolar cycloaddition reaction, tracking by TLC (thin-layer chromatography), removing the solvent by reduced pressure rotary distillation after the reaction is completed, dissolving 3mL of ethyl acetate for standby application, and finally dissolving with V(Ethyl acetate):V(Petroleum ether)Separating by 1:5 silica gel column chromatography to obtain p-chlorophenyl substituted spiro [ indazole-isoxazole containing chromone structure]And (3) derivatives.
The experimental data are as follows: a p-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative (compound 4) as a pale yellow powder in 72.5% yield, melting point: 186 ℃ and 187 ℃, the nuclear magnetic hydrogen spectrum data and the element analysis data are as follows:
1H NMR(CDCl3):8.21(s,1H,N＝C-H),7.49-7.21(m,12H,Ar-H),6.54(s,1H),6.47(s,1H,C＝C-H),3.12-3.14(m,2H),3.05(t,J＝6.5Hz,2H).
IR(KBr)v/cm-1 3105(ArH),1676(C＝O),1631,1580,1462(C＝N,C＝C),
m/e:599(100.0％)
Anal.calcd.for C30H19BrClN3O4：C,59.97；H,3.19；N,6.99；found C,59.99；H,3.22；N,6.95。
in this example, MTT method is used to determine the in vitro inhibitory effect of p-chlorophenyl-substituted spiro [ indazole-isoxazole ] derivative containing chromone structure on different tumor strains, and the determination result of the antitumor activity of p-chlorophenyl-substituted spiro [ indazole-isoxazole ] derivative containing 6-bromochromone structure is as follows:
p-chlorophenyl substituted spiro [ indazole-isoxazole ] containing chromone structure]The derivatives were dissolved and diluted in DMSO, and tumor cells KB (oral cancer cells), SGC7901 (gastric cancer cells), HCT116 (colon cancer cells), Bel-7402 (human liver cancer cells), HO8901 (ovarian cancer cells), K562 (leukemia cells) were seeded in 4000/200. mu.L/well in 96-well plates, 2. mu.L of compound was added to each well to a final concentration of 12.0. mu.M, 6.0. mu.M, 3.0. mu.M, 1.5. mu.M, together at 37 ℃ with 5% CO2The cells were incubated in an incubator for 72 hours, with DMSO (1%) as a blank control. After 72 hours, MTT was added to a final concentration of 0.25mg/mL and the mixture was left at 37 ℃ with 5% CO2After 4 hours in the cell incubator, the solvent was blotted, 100. mu.l DMSO was added to each well, absorbance (OD value) was measured at 570nm with an enzyme-linked immunosorbent assay, and the data obtained was used to calculate IC50The value is obtained. Selecting compounds with high inhibitory activity, and determining the influence of different action times of the compounds at different concentrations on the human tumor cell cycle and apoptosis.
The test compounds of different concentrations were coarse-screened in 96-well plates and IC was calculated from the resulting inhibition50The results are shown in Table 1 below (p-chlorophenyl substituted spiro [ indazole-isoxazole ] containing chromone structure]IC of derivatives on six tumor cell lines50Value).
TABLE 1
In Table 1, spiro [ indazole-isoxazole having a p-chlorophenyl-substituted chromone-containing structure is shown]IC of derivative (Compound 4) against six tumor cell lines50The values show that the compound has stronger tumor cell inhibiting effect on HCT116 (colon cancer cells) and Bel-7402 (human liver cancer cells), and is a further medicineThe field application provides the foundation.
In vitro anti-inflammatory Activity assay
Cell proliferation is a complex process, and the whole process is regulated by a network of signal paths, including extracellular signals and intracellular cascade amplification signals. Blocking the transmission of cell proliferation signals can inhibit the proliferation of RAW264.7 cells and reduce inflammation, thereby having anti-inflammatory effect.
Experimental procedure, test sample Compound 4. RAW264.7 cells were divided into 6 experimental groups, namely Control group, LPS group, and LPS + sample groups of different concentrations (5, 10, 20, 40 ug/mL). Culturing RAW264.7 cells in DMEM medium to logarithmic phase, digesting with digestive juice containing pancreatin 0.25% and EGTA-Na 0.01%, washing with DMEM medium, centrifuging, adjusting appropriate cell density, inoculating into 96-well plate, 200 μ L/well, standing at 37 deg.C, saturation humidity, and 5% CO2The incubator is used for 24 h. Adding 10 μ L of samples with different concentrations (concentration of 5, 10, 20, 40 μ g/mL, each concentration having 3 multiple wells at 37 deg.C and 5% CO)2Incubate the incubator for 24 hours.
This example uses the MTT method to test the effect of samples on LPS-stimulated RAW264.7 cell proliferation: after 24h of LPS (10. mu.g/mL), 20. mu. of LMTT working solution was added to each well, and the mixture was left at 37 ℃ under saturated humidity and 5% CO2The incubator is used for 24 h. After centrifugation and aspiration of the supernatant, 100. mu.L of dimethyl sulfoxide (DMSO) was added to each well, and after complete dissolution, the absorbance (A value) was measured at 492nm using a microplate reader to calculate the cell inhibitory rate of each group.
The cell inhibition rate (1-experimental group a mean/control group a mean) × 100% gave the results of the effect of the compound on LPS-stimulated RAW264.7 cell proliferation, as shown in table 2.
TABLE 2
The compound 4 can inhibit cell proliferation induced by LPS, has better in-vitro anti-inflammatory activity and is dose-dependent, and provides a foundation for further application in the medical field.
The above embodiments are only for illustrating the technical solution of the present invention and not for limiting the same, and those skilled in the art can make various corresponding changes and modifications according to the present invention without departing from the spirit and the essence of the present invention, but these corresponding changes and modifications should fall within the protection scope of the appended claims.
Claims (4)
1. The p-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative is characterized in that the chemical structural formula of the p-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative is as follows:
wherein: ar =4-ClC6H4-。
2. A process for preparing p-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivatives according to claim 1, comprising the steps of:
(1) synthesis of 6-bromo-4-oxo-4H-benzopyran-3-carbaldehyde oxime: adding 50.0mL of 6-bromo-4-oxo-4H-benzopyran-3-formaldehyde into ethanol, completely dissolving 316.0mg of hydroxylamine hydrochloride and 464.0mg of sodium acetate in distilled water, dropwise adding the solution into the former solution by using a constant-pressure dropping funnel, heating, refluxing, tracking by TLC (thin layer chromatography), cooling to room temperature after the reaction is finished, carrying out suction filtration, washing with water, and recrystallizing a product by using 95% ethanol to obtain 6-bromo-4-oxo-4H-benzopyran-3-formaldehyde oxime;
(2)5- (4-chlorobenzylidene) -1-phenyl-6, 7-dihydro-1HSynthesis of-indazol-4 (5H) -one: mixing 10mmol 1-phenyl-6, 7-dihydro-1HDissolving (E) -indazole-4 (5H) -ketone and 10mmol of p-chlorobenzaldehyde in 10mL of ethanol, adding 2mL of 40% NaOH aqueous solution by mass fraction, stirring at 80 ℃ for 3 hours, filtering and separating by using a Buchner funnel, washing a filter cake with water, recrystallizing and purifying by using ethanol, filtering and drying to obtain a product 5- (4-chlorobenzylidene) -1-phenyl-6, 7-dihydro-1H-indazole-4 (5)H)-a ketone;
(3) to 30mL of absolute ethanol was added 5- (4-chlorobenzylidene) -1-phenyl-6, 7-dihydro-1HDissolving (E) -indazole-4 (5H) -one and 6-bromo-4-oxo-4H-benzopyran-3-formaldehyde oxime, adding chloramine T inorganic salt, refluxing for 12 hours, performing 1, 3-dipolar cycloaddition reaction, tracking by TLC (thin layer chromatography), removing the solvent by reduced pressure rotary distillation after the reaction is completed, dissolving 3mL ethyl acetate for later use, and finally separating by silica gel column chromatography with a developing agent to obtain the spiro [ indazole-isoxazole-p-chlorophenyl substituted chromone structure]And (3) derivatives.
3. The process for preparing p-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivatives according to claim 2, wherein: in the step (3), the ratio of the chloramine T inorganic salt to the 6-bromo-4-oxo-4H-benzopyran-3-formaldehyde oxime to the 5- (4-chlorobenzylidene) -1-phenyl-6, 7-dihydro-1H-indazol-4 (5H) -one substance is 7:6: 5.
4. The p-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole of claim 2]A process for the preparation of derivatives, characterized in that: the developing solvent in the step (3) is ethyl acetate and petroleum ether, and the volume ratio of the ethyl acetate to the petroleum ether is V(Ethyl acetate): V(Petroleum ether)=1:5。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910530410.XA CN110128445B (en) | 2019-06-19 | 2019-06-19 | P-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910530410.XA CN110128445B (en) | 2019-06-19 | 2019-06-19 | P-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110128445A CN110128445A (en) | 2019-08-16 |
| CN110128445B true CN110128445B (en) | 2020-12-08 |
Family
ID=67578102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910530410.XA Active CN110128445B (en) | 2019-06-19 | 2019-06-19 | P-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110128445B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103554135B (en) * | 2013-11-15 | 2016-01-20 | 绍兴文理学院 | A kind of containing chromone structure isoxazole norcantharidin derivative and preparation method thereof and application |
-
2019
- 2019-06-19 CN CN201910530410.XA patent/CN110128445B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110128445A (en) | 2019-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110128444B (en) | P-nitrophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, and preparation method and application thereof | |
| CN110183467B (en) | P-methoxyphenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, and preparation method and application thereof | |
| CN110128445B (en) | P-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, and preparation method and application thereof | |
| CN110256462B (en) | Para-fluorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, and preparation method and application thereof | |
| CN110143971B (en) | Methylthiophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, and preparation method and application thereof | |
| CN110642864B (en) | Spiro [ indazole-pyrazoline ] derivative containing pyrazole structure and preparation method and application thereof | |
| CN110128447B (en) | P-methylphenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, and preparation method and application thereof | |
| CN110156812B (en) | Spiro [ indazole-isoxazole ] derivative containing chromone structure, and preparation method and application thereof | |
| CN110128446B (en) | 3,4, 5-trimethoxy phenyl substituted spiro [ indazole-isoxazole ] derivative containing chromone structure, and preparation method and application thereof | |
| CN106083884B (en) | A kind of D-Leu ring substituent norcantharidin derivative and the preparation method and application thereof | |
| CN106220642B (en) | A kind of L-Leu ring substituent norcantharidin derivative and the preparation method and application thereof | |
| CN112062799B (en) | Methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative and preparation method and application thereof | |
| CN110759920A (en) | P-methoxyphenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure and preparation method and application thereof | |
| CN112645957A (en) | Pyridazinone structure-containing spiropyrazole-pyrrolizine derivative and preparation method and application thereof | |
| CN110790769B (en) | P-methylphenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure and preparation method and application thereof | |
| CN110655522B (en) | O-chlorophenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure and preparation method and application thereof | |
| CN110724148B (en) | P-chlorophenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure and preparation method and application thereof | |
| CN110734442B (en) | 3,4, 5-trimethoxyphenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure, and preparation method and application thereof | |
| CN106046019B (en) | A kind of Valine ring substituent norcantharidin derivative and the preparation method and application thereof | |
| CN110746431B (en) | P-methylmercapto phenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure and preparation method and application thereof | |
| CN111961101B (en) | Spiroisoxazole-pyrrolizine derivative with arabinose triazole structure as well as preparation method and application thereof | |
| CN111909230B (en) | Chlorine-substituted arabinose triazole structure spiro isoxazole-pyrrolizine derivative and preparation method and application thereof | |
| CN112028955B (en) | Trimethoxylated arabinose triazole structure spiroisoxazole-pyrrolizine derivative and preparation method and application thereof | |
| CN111961099B (en) | Methyl-substituted arabinose triazole structure spiro isoxazole-pyrrolizine derivative and preparation method and application thereof | |
| CN109053732B (en) | Para-fluorine substituted pyridazinone structure-containing spiro [ indolizine-pyrazoline ] derivative and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211118 Address after: 250000 1422, building n, Hengda City, No. 58, Gongye North Road, Licheng District, Jinan City, Shandong Province Patentee after: Jinan Weiyang Technology Co.,Ltd. Address before: 312000 No. 508 West Ring Road, Zhejiang, Shaoxing Patentee before: SHAOXING University |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211214 Address after: 450000 room 2625, second floor, administrative service center, South Yingbin Road, HANGGANG District, Zhengzhou City, Henan Province Patentee after: HENAN METAB BIOPHARMA Co.,Ltd. Address before: 250000 1422, building n, Hengda City, No. 58, Gongye North Road, Licheng District, Jinan City, Shandong Province Patentee before: Jinan Weiyang Technology Co.,Ltd. |